Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the t(9;22) translocation coding for the chimeric protein p210 BCR-ABL. The tumor suppressor PTEN plays a critical role in the pathogenesis of CML chronic phase, through non genomic loss of function mechanisms, such as protein down-regulation and impaired nuclear/cytoplasmic shuttling. Here we demonstrate that BCR-ABL promotes PTEN downregulation through a MEK dependent pathway. Furthermore, we describe a novel not recurrent N212D-PTEN point mutation found in the EM2 blast crisis cell line.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208795 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0110682 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Cotargeting of thioredoxin 1 and glutamate-cysteine ligase in both imatinib-sensitive and imatinib-resistant CML cells.
Biochem Pharmacol
January 2025
Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang, RP China; State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, PR China. Electronic address:
Chronic myeloid leukemia (CML) is a type of malignancy characterized by harboring the oncogene Bcr-Abl, which encodes the constitutively activated tyrosine kinase BCR-ABL. Although tyrosine kinase inhibitors targeting BCR-ABL have revolutionized CML therapy, native and acquired drug resistance commonly remains a great challenge. Thioredoxin 1 (Trx1) and glutamate-cysteine ligase (GCL), which are two major antioxidants that maintain cellular redox homeostasis, are potential targets for cancer therapy and overcoming drug resistance.
View Article and Find Full Text PDFCardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?
ESC Heart Fail
January 2025
Cardiology Unit, University Hospital 'Paolo Giaccone', Palermo Italy and Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE) University of Palermo, Palermo, Italy.
Aims: Knowledge of the effects of sex in cardio-oncology is limited, particularly in patients treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukaemia (CML). This study aims to evaluate the influence of gender differences on the incidence of cardiovascular toxicity in patients with CML.
Methods: The study population consisted of 148 patients (45% women, mean age: 58 ± 14.
PRMT1 Promotes the Self-renewal of Leukemia Stem Cells by Regulating Protein Synthesis.
Adv Sci (Weinh)
December 2024
State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, 510632, China.
The application of tyrosine kinase inhibitors (TKIs) has revolutionized the management of chronic myeloid leukemia (CML). However, disease relapse and progression particularly due to persistent leukemia stem cells (LSCs) remain a big challenge in the clinic. Therefore, validation of the therapeutic vulnerability in LSCs is urgently needed.
View Article and Find Full Text PDFInvestigation of TSRP reverses imatinib resistance through the PI3K / Akt pathway in chronic myeloid leukemia.
Ann Hematol
December 2024
Department of Traditional Chinese Medicine (TCM) Pharmacy, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, 310003, China.
Article Synopsis
- * Research is exploring the use of traditional Chinese medicine, specifically total saponin of L. (TSRP), which has shown promise in inhibiting CML cell growth and potentially reversing imatinib resistance.
- * This project aims to understand how TSRP impacts the PI3K/AKT signaling pathway, which is linked to imatinib resistance, through in vitro and in vivo experiments, to support TSRP's use alongside imatinib in CML treatment.
Mebendazole effectively overcomes imatinib resistance by dual-targeting BCR/ABL oncoprotein and β-tubulin in chronic myeloid leukemia cells.
Korean J Physiol Pharmacol
January 2025
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Article Synopsis
- Tyrosine kinase inhibitors (TKIs) are key treatments for chronic myeloid leukemia (CML), but resistance and intolerance to these drugs pose significant challenges.
- This research highlights the potential of re-purposed drug mebendazole (MBZ) as an effective anti-cancer agent that can work against both imatinib-sensitive and imatinib-resistant CML cells.
- MBZ was found to inhibit cell proliferation and induce cell death by targeting BCR/ABL activity, disrupting microtubule formation, and increasing DNA damage, presenting a novel approach for treating TKI-resistant CML patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!